BioMimetic Therapeutics specializes in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases. The Augment® product line is based on recombinant human platelet-derived growth factor (rhPDGF-BB), a synthetic copy of one of the body’s principal healing agents. MB Venture Partners led BioMimetic’s Series B round of financing in May 2003. As of March 1, 2013, BioMimetic Therapeutics, Inc. is now part of Wright Medical Group, Inc. (NASDAQ: WMGI).
BioMimetic successfully completed an IPO in May 2006. We sold our BioMimetic shares and distributed cash to Fund I investors in mid-2007.